Abstracts Archive - Page 867 of 2425 - ACR Meeting Abstracts

Abstract Number: 1629 • 2019 ACR/ARP Annual Meeting
Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
Yasser Radwan¹, Tina Gunderson ², Cynthia Crowson ³, Alicia Hinze ¹, Kevin Moder ⁴, Floranne Ernste ⁴, Shreyasee Amin ⁴, Uma Thanarajasingam ², Thomas Osborn ¹, Kenneth Warrington ⁴, Paul Wennberg ⁴ and Ashima Makol ¹, ¹Mayo Clinic Minnesota, rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic Rochester, rochester, MN
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a simple, non-invasive & highly sensitive tool to evaluate structural abnormalities of the microcirculation in vivo and considered a key…
Abstract Number: 1630 • 2019 ACR/ARP Annual Meeting
Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Takashi Nawata¹, Mikito Suzuki ², Yuichiro Shirai ³ and Masataka Kuwana ³, ¹1. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. 2. Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is the leading causes in patients with systemic sclerosis (SSc). Forced vital capacity (FVC) is routinely used for assessment of…
Abstract Number: 1631 • 2019 ACR/ARP Annual Meeting
Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis
Victoria Flower¹, Shaney Barratt ², Darren Hart ³, Amanda Mackenzie ⁴, Jacqueline Shipley ³, Stephen Ward ⁴ and John Pauling ¹, ¹Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ²North Bristol NHS Trust, Bristol, England, United Kingdom, ³Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ⁴Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, England, United Kingdom
Background/Purpose: There have been a number of recent negative clinical trials of SSc utilising the modified Rodnan Skin Score. High Frequency Ultrasound (HFUS) allows objective…
Abstract Number: 1632 • 2019 ACR/ARP Annual Meeting
Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Toby M. Maher ², Edward E. Philpot ³, Ali Ashrafzadeh ⁴ and Oliver Distler ⁵, ¹Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²National Heart and Lung Institute, Imperial College London; Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK, London, United Kingdom, ³Respiratory Center of Excellence, IQVIA, Durham, NC, USA, Durham, NC, ⁴Rheumatology Center of Excellence, IQVIA, San Diego, CA, USA, San Diego, CA, ⁵Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Guidelines are needed to aid early recognition and treatment of interstitial lung disease in systemic sclerosis (SSc-ILD). This study was conducted to develop expert…
Abstract Number: 1633 • 2019 ACR/ARP Annual Meeting
Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis
Tetsuya Furukawa¹, Yuichi Yokoyama ², Teppei Hashimoto ³, Naoto Azuma ⁴ and Kiyoshi Matsui ⁴, ¹Hyogo College of Medicine, Nishinomiya, Japan, ²Hyogo College of Medicine, Kyoto, Japan, ³Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Kobe, Hyogo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
Background/Purpose: Systemic sclerosis (SSc) is an intractable connective tissue disease that causes skin and organ fibrosis, and its prognosis is affected by pulmonary hypertension (PH).…
Abstract Number: 1634 • 2019 ACR/ARP Annual Meeting
Comparison of Different Pulmonary Hypertension Screening Algorithms in Patients with Systemic Sclerosis
Mustafa Erdogan¹, Burcak Kilickiran Avci ², Yagmur Ersoy ³, Cansu Ebren ², Zeki Ongen ², Gul Ongen ⁴, Vedat Hamuryudan ⁵ and Gulen Hatemi ⁶, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheuma, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Cardiology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Chest Diseases, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Pulmonary hypertension (PH) is an important cause of morbidity and mortality in patients with systemic sclerosis (SSc). Different screening algorithms have been proposed for…
Abstract Number: 1635 • 2019 ACR/ARP Annual Meeting
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
Barbara Ruaro¹, Elisa Alessandri ², Massimo Ghio ³, Carmen Pizzorni ⁴, Sabrina Paolino ⁴, Andrea Casabella ⁵, Antonio De Tanti ⁶, Alberto Sulli ⁷ and Maurizio Cutolo ⁸, ¹1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, ²1. Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁵1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Fontanellato, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: To evaluate any correlation between the Raynaud's Condition Score (RCS) and the morphological and functional methods available to evaluate microvascular damage in systemic sclerosis (SSc) patients (1-4). Methods: Sixty-six…
Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Maureen Mayes¹, Kristin Highland ², Martina Gahlemann ³, Aryeh Fischer ⁴, Ganesh Raghu ⁵, Mannaig Girard ⁶, Margarida Alves ⁷, Susanne Stowasser ⁷, Jörg Distler ⁸, Marco Matucci-Cerinic ⁹, Elizabeth Volkmann ¹⁰, Masataka Kuwana ¹¹ and Oliver Distler ¹², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁵University of Washington, Seattle, USA, Seattle, ⁶Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ¹⁰University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
Abstract Number: 1637 • 2019 ACR/ARP Annual Meeting
The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy
Masanari Kodera¹, Yoshihito Tanaka ², Yumi Ito ², Miho Sugata ², Satoko Hisada ², Naohisa Ichiki ² and Toshiaki Tanabe ², ¹Japan Community Health care Organization Chukyo Hospital, Department of Dermatology and Rheumatology, Aichi, Japan, ²Japan Community Health care Organization Chukyo hospital, Nagoya, Japan
Background/Purpose: Systemic Sclerosis (SSc) patients with anti-RNA polymerase III (RNAP) antibody have been reported to have an increased risk of malignancy as compared with those…
Abstract Number: 1638 • 2019 ACR/ARP Annual Meeting
Sexual Health in 60 Female Patients with Systemic Sclerosis
Barbora Hermankova ¹, Maja Spiritovic ², Hana Storkanova ³, Sabina Oreska ⁴, Petr Cesak ¹, Karel Pavelka ⁴, Jiří Vencovský ⁴, Ladislav Senolt ⁴, Radim Becvar ⁴ and Michal Tomcik⁴, ¹Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is a chronic, multisystem, connective tissue disorder characterized by fibrosis of the skin and internal organ involvement, which can influence all…
Abstract Number: 1639 • 2019 ACR/ARP Annual Meeting
Endoscopic Findings in a Scleroderma Cohort with and Without Interstitial Lung Disease
Manpreet Parmar¹, Miruna Carnaru ², Anand Patel ³ and Vivien Hsu ⁴, ¹Rutgers-RWJ Medical School, Matawan, NJ, ²Yale University, New Haven, CT, ³Temple, Philadelphia, PA, ⁴Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ
Background/Purpose: Gastro-intestinal (GI) involvement is universal in systemic sclerosis (SSc) and may affect the entire length of the bowel, most commonly the esophagus (1). The…
Abstract Number: 1640 • 2019 ACR/ARP Annual Meeting
Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease
Cristina Hidalgo¹, Lucía López Corral ², Concepción Roman ², Luis Gómez-Lechón ³, Maria Elisa Acosta ⁴, Olga Compan ⁵, Estefania Pérez ², Carlos Montilla ⁴ and Maria Dolores Caballero ⁶, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³Hospital Universiatrio, Salamanca, Castilla y Leon, Spain, ⁴Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁵Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, ⁶Hispital Universitario, Salamanca, Castilla y Leon, Spain
Background/Purpose: Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HCT). Clinically, cGVHD is a…
Abstract Number: 1641 • 2019 ACR/ARP Annual Meeting
Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis
Antonia Valenzuela¹, Melody Chung ², Tatiana S. Rodríguez-Reyna ³, Susanna Proudman ⁴, Murray Baron ⁵, Flavia Castelino ⁶, Vivien Hsu ⁷, Shufeng Li ⁸, David Fiorentino ⁹, Kathryn Stevens ¹⁰ and Lorinda Chung ², ¹Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile, ²Stanford University, Palo Alto, CA, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁵Jewish General Hospital, McGill University, Montreal, Canada, ⁶Harvard University, Boston, MA, ⁷Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ⁸Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA, ⁹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ¹⁰Stanford University, Stanford
Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients, most frequently involving the hands. We previously developed and…
Abstract Number: 1642 • 2019 ACR/ARP Annual Meeting
Automated Nailfold Capillary Counting System (AUTOCAPI) in Systemic Sclerosis Patients with Different Capillaroscopic Patterns
Alberto Sulli¹, Amber Vanhaecke ², Carmen Pizzorni ³, Giorgia Ferrari ⁴, Veronica Tomatis ⁵, Monica Pendolino ⁴, Vanessa Smith ⁶ and Maurizio Cutolo ⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ²Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium, Ghent, Belgium, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Genoa, Italy, ⁶Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium
Background/Purpose: Nailfold videocapillaroscopy (NVC) allows assessment of possible microvascular markers of severity and progression in systemic sclerosis (SSc), such as reduced capillary number, which has…
Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Madelon Vonk¹, Oliver Distler ², Daniel Furst ³, Eric Hachulla ⁴, Sindhu Johnson ⁵, Shervin Assassi ⁶, Leslie Meng ⁷, Manuel Quaresma ⁸, Margarida Alves ⁸, Emmanuelle Clerisme-Beaty ⁸ and Wim Wuyts ⁹, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³University of California, Los Angeles, CA, ⁴Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ⁵Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].